Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Allerderm |
---|---|
Information provided by: | Allerderm |
ClinicalTrials.gov Identifier: | NCT00640250 |
We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").
Condition | Intervention | Phase |
---|---|---|
Contact Dermatitis |
Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Double Blind (Subject, Investigator), Single Group Assignment, Safety Study |
Official Title: | Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study |
Estimated Enrollment: | 40 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Sensitives: Experimental
Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
|
Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2 Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours. |
Primary endpoint:
To evaluate the diagnostic performance of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:
Secondary endpoint:
To evaluate the safety of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
OR Current or previous symptoms and/or history consistent with allergic contact dermatitis, and a positive patch test (within the past 5 years) to Disperse blue 106 or Disperse blue 106/124 allergen mix.
Exclusion Criteria:
Contact: Kim M Sullivan, BA | +1 602-225-0595 ext 274 | sullivan@smarthealth.com |
Contact: Heather Schutten | +1 602-225-0595 ext 302 | hschutte@smarthealth.com |
United States, Kentucky | |
Dermatology Specialists PSC | Recruiting |
Louisville, Kentucky, United States, 40202-1864 | |
Contact: Jennifer Goyne 502-583-7546 ext 158 dermresearch@msn.com | |
Contact: Lynn Fowler +1 502-583-7546 lynnmfowler@msn.com | |
Principal Investigator: Joseph Fowler, MD | |
Denmark | |
Odense University Hospital | Recruiting |
Odense C, Denmark, DK-5000 | |
Contact: Evy Paulsen, MD, Ph.D +45 65 41 27 08 Evy.Paulsen@ouh.regionsyddanmark.dk | |
Contact: Klaus E Andersen, MD, Ph.D +45 65 41 27 00 Klaus.Ejner.Andersen@ouh.regionsyddanmark.dk | |
Principal Investigator: Evy Paulsen, MD, Ph.D | |
Sub-Investigator: Klaus E Andersen, MD, Ph.D | |
Sub-Investigator: Charlotte G Mørtz, MD, Ph.D |
Principal Investigator: | Evy Paulsen, M.D., Ph.D | Odense University Hospital |
Principal Investigator: | Joseph Fowler, MD | Dermatology Specialists PSC |
Responsible Party: | Allerderm ( Kim M Sullivan/ Study Coordinator ) |
Study ID Numbers: | Mekos 07 2P3.2 201, BB-IND#: 13546, Eudra CT#: 2007-007130-19, WIRB Pr. No.: 20072233 |
Study First Received: | March 3, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00640250 History of Changes |
Health Authority: | United States: Food and Drug Administration; Denmark: Danish Dataprotection Agency; Denmark: Danish Medicines Agency; Denmark: Ethics Committee |
Dermatitis, Contact, Bronopol, Disperse Blue 106 |
Skin Diseases Skin Diseases, Eczematous Dermatitis, Contact Dermatitis |
Skin Diseases Skin Diseases, Eczematous Dermatitis, Contact Dermatitis |